MOLECULAR PATHOLOGY OF ACUTE PROMYELOCYTIC LEUKEMIA
MOLECULAR PATHOLOGY OF ACUTE PROMYELOCYTIC LEUKEMIA
批准号:
2654082
负责人:
KUN-SANG CHANG
金额:
$18.04万
依托单位国家:
美国
项目类别:
财政年份:
1992
资助国家:
美国
项目状态:
已结题
起止时间:
1992-09-01 至 2000-01-31
关键词:
3T3 cells acute myelogenous leukemia apoptosis cell differentiation cell growth regulation chimeric proteins chromosome translocation disease /disorder model genetic promoter element growth factor receptors growth inhibitors human tissue molecular oncology molecular pathology mutant neoplastic cell phosphorylation site directed mutagenesis tissue /cell culture transfection
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (adapted from the investigator's abstract) Nonrandom
chromosomal translocation plays a major role in the pathogenesis of
acute leukemia. However, the molecular mechanism of pathogenesis is
relatively unknown. Studies on the molecular pathology of acute
promyelocytic leukemia (APL) strongly support the importance of the
fusion protein PML-RARalpha, encoded from the t(15;17), in the
development of APL. Based on the finding by the investigators that PML
is a growth suppressor and results reported from others, a model of APL
pathogenesis was proposed. In this model, PML-RARalpha plays a central
role as a dominant negative inhibitor against PML and RXR. Sequestration
of these two proteins results in growth stimulation and differentiation
block at the promyelocyte stage which leads to APL pathogenesis. This
model represents the first to emphasize the importance of a dominant
negative inhibitor in the development of acute leukemia. The
investigator's finding that PML is a growth suppressor may contribute to
a better understanding of APL pathogenesis. Studies on the biologic
function of PML will provide critical information to further understand
APL. The two major goals of this proposal are: (1) to elucidate the
molecular mechanism of APL pathogenesis. Experiments are designed to
support the proposed model using dominant negative inhibitors against
PML, RARalpha (or RXR), and a mutant PML-RARalpha driven by an inducible
promoter. Stable transfectants of these mutants will be established to
investigate their effect on growth and differentiation of human leukemia
cells and primary fibroblasts. The effect of over-expression of RXR and
PML in the APL-derived NB4 cells on clonogenicity, differentiation and
growth will be investigated. Dominant negative mutants of PML, RARalpha
and cell lines are available in the laboratory for this study. (2) To
study the biologic function of PML. Results demonstrated a highest number
of PODs at the G1 phase; a nuclear diffused PML pattern at the S phase
coincided with a decreased in PODs; a significant increased in PODs
shortly after gamma-irradiation and that both tyrosine and serine
residues of PML are phosphorylated. These findings suggest that
modification of PML during cell cycle progression may be important for
its biologic function. The participants propose to investigate the role
of phosphorylation on the biologic function of PML. Site directed
mutagenesis will be performed to identify and to alter the phosphoamino
acid to a nonphosphorylated form. Their ability to form PODs in NIH/3T3
cells and to suppress transformation by neu will be investigated. It will
be investigated as to whether PML is phosphorylated by a cell cycle
related kinase. PML deletion mutants have been created, we found that
the ability of PML to form POD is essential for its transformation
suppressor function. The investigators will continue to study their
effect on suppressing transcription activity of EGFR promoter. Stable
transfectants of PML in NB4 cells will be used to investigate whether PML
induces differentiation, apoptosis, or cell cycle arrest. Its effect on
tumorigenicity and clonogenicity will also be investigated. The
investigators have found that PML enhances cell survival after radiation
exposure, and will investigate whether PML affect cell cycle distribution
and inhibits apoptosis in these cells. Finally, identification and
characterization of the PML associated proteins by 32P-labelled PML probe
and by the yeast two-hybrid system will carried out.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of Gene Expression by PML
-
批准号:6942449
-
项目类别:
-
资助金额:$30.24万
-
财政年份:2003
-
负责人:KUN-SANG CHANG
-
依托单位:
Regulation of Gene Expression by PML
-
批准号:6807029
-
项目类别:
-
资助金额:$30.24万
-
财政年份:2003
-
负责人:KUN-SANG CHANG
-
依托单位:
Regulation of Gene Expression by PML
-
批准号:7246574
-
项目类别:
-
资助金额:$28.67万
-
财政年份:2003
-
负责人:KUN-SANG CHANG
-
依托单位:
Regulation of Gene Expression by PML
-
批准号:7118005
-
项目类别:
-
资助金额:$29.53万
-
财政年份:2003
-
负责人:KUN-SANG CHANG
-
依托单位:
Regulation of Gene Expression by PML
-
批准号:6731288
-
项目类别:
-
资助金额:$30.24万
-
财政年份:2003
-
负责人:KUN-SANG CHANG
-
依托单位:
MOLECULAR PATHOLOGY OF ACUTE PROMYELOCYTIC LEUKEMIA
-
批准号:6192152
-
项目类别:
-
资助金额:$22.84万
-
财政年份:1992
-
负责人:KUN-SANG CHANG
-
依托单位:
A Role for PML in Genome Stability and DNA Damage Response
-
批准号:8215849
-
项目类别:
-
资助金额:$25.61万
-
财政年份:1992
-
负责人:KUN-SANG CHANG
-
依托单位:
MOLECULAR PATHOLOGY OF ACUTE PROMYELOCYTIC LEUKEMIA
-
批准号:2330801
-
项目类别:
-
资助金额:$17.5万
-
财政年份:1992
-
负责人:KUN-SANG CHANG
-
依托单位:
MOLECULAR PATHOLOGY OF ACUTE PROMYELOCYTIC LEUKEMIA
-
批准号:2871764
-
项目类别:
-
资助金额:$18.76万
-
财政年份:1992
-
负责人:KUN-SANG CHANG
-
依托单位:
A Role for PML in Genome Stability and DNA Damage Response
-
批准号:7373528
-
项目类别:
-
资助金额:$26.41万
-
财政年份:1992
-
负责人:KUN-SANG CHANG
-
依托单位:
MOLECULAR PATHOLOGY OF ACUTE PROMYELOCYTIC LEUKEMIA
-
批准号:3200074
-
项目类别:
-
资助金额:$15.59万
-
财政年份:1992
-
负责人:KUN-SANG CHANG
-
依托单位:
MOLECULAR PATHOLOGY OF ACUTE PROMYELOCYTIC LEUKEMIA
-
批准号:2096700
-
项目类别:
-
资助金额:$15.24万
-
财政年份:1992
-
负责人:KUN-SANG CHANG
-
依托单位:
MOLECULAR PATHOLOGY OF ACUTE PROMYELOCYTIC LEUKEMIA
-
批准号:6375916
-
项目类别:
-
资助金额:$23.08万
-
财政年份:1992
-
负责人:KUN-SANG CHANG
-
依托单位:
MOLECULAR PATHOLOGY OF ACUTE PROMYELOCYTIC LEUKEMIA
-
批准号:6613828
-
项目类别:
-
资助金额:$6.67万
-
财政年份:1992
-
负责人:KUN-SANG CHANG
-
依托单位:
MOLECULAR PATHOLOGY OF ACUTE PROMYELOCYTIC LEUKEMIA
-
批准号:6801991
-
项目类别:
-
资助金额:$21.39万
-
财政年份:1992
-
负责人:KUN-SANG CHANG
-
依托单位:
A Role for PML in Genome Stability and DNA Damage Response
-
批准号:8016093
-
项目类别:
-
资助金额:$25.61万
-
财政年份:1992
-
负责人:KUN-SANG CHANG
-
依托单位:
A Role for PML in Genome Stability and DNA Damage Response
-
批准号:7195966
-
项目类别:
-
资助金额:$26.41万
-
财政年份:1992
-
负责人:KUN-SANG CHANG
-
依托单位:
A Role for PML in Genome Stability and DNA Damage Response
-
批准号:7779991
-
项目类别:
-
资助金额:$26.41万
-
财政年份:1992
-
负责人:KUN-SANG CHANG
-
依托单位:
MOLECULAR PATHOLOGY OF ACUTE PROMYELOCYTIC LEUKEMIA
-
批准号:2096702
-
项目类别:
-
资助金额:$19.3万
-
财政年份:1992
-
负责人:KUN-SANG CHANG
-
依托单位:
MOLECULAR PATHOLOGY OF ACUTE PROMYELOCYTIC LEUKEMIA
-
批准号:6929092
-
项目类别:
-
资助金额:$21.63万
-
财政年份:1992
-
负责人:KUN-SANG CHANG
-
依托单位:
海外基金